Otium Capital

Tracked participation in 1 Atlas company, with 1 explicitly attributed lead.

1portfolio companies

2round participations

1lead positions

$11Mled round total

Conviction

Most recent leads

The latest rounds this investor is sourced as leading, newest first.

Jan 2018OwkinSeries A$11M

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

OOwkinScienceOwkin is a privately held AI company building “agentic” biological AI products for drug discovery, clinical…$1Bvaluation$635.2MraisedRecent roundsTotal disclosed (company press kit aggregate) · null$304.1M · Bpifrance Large Ventures, Bristol-Myers Squibb +10Spin-out financing: Waiv (formerly Owkin Dx) · Mar 2026$33M · led by Alpha Intelligence Capital, OTB VenturesStrategic collaboration with Bristol Myers Squibb (incl. Series B-1 equity investment) · Jun 2022$80M · led by Bristol Myers SquibbOwkin—Jan 2018 → null2 rounds1 led—

DateCompanyRoundRaisedValuationRoleEvidence

nullOOwkinScienceOwkin is a privately held AI company building “agentic” biological AI products for drug discovery, clinical…$1Bvaluation$635.2MraisedRecent roundsTotal disclosed (company press kit aggregate) · null$304.1M · Bpifrance Large Ventures, Bristol-Myers Squibb +10Spin-out financing: Waiv (formerly Owkin Dx) · Mar 2026$33M · led by Alpha Intelligence Capital, OTB VenturesStrategic collaboration with Bristol Myers Squibb (incl. Series B-1 equity investment) · Jun 2022$80M · led by Bristol Myers SquibbOwkinTotal disclosed (company press kit aggregate)$304.1M—Participant

Source ↗

Jan 16, 2018OOwkinScienceOwkin is a privately held AI company building “agentic” biological AI products for drug discovery, clinical…$1Bvaluation$635.2MraisedRecent roundsTotal disclosed (company press kit aggregate) · null$304.1M · Bpifrance Large Ventures, Bristol-Myers Squibb +10Spin-out financing: Waiv (formerly Owkin Dx) · Mar 2026$33M · led by Alpha Intelligence Capital, OTB VenturesStrategic collaboration with Bristol Myers Squibb (incl. Series B-1 equity investment) · Jun 2022$80M · led by Bristol Myers SquibbOwkinSeries A$11M—Lead

Source ↗

DateCompanyRoundRaisedValuationRoleEvidence

Source ↗